In follow-up experiments with HAP1 cells and different cancer cells, we found that TRPM7 regulates the expression of HER2 and that this regulatory mechanism can be exploited for combinatorial pharmacological treatment of HER2-expressing breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.